

REMARKS

The claims have been amended to conform to the election. In the event a species selection is required, applicants elect the species of claim 40, wherein the disorder is arthritis.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 391442001122.

Respectfully submitted,

Dated: April 17, 2002

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

31. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of [a compound of. AMD 3100 (](1,1'-[1,4-phenylenebis(methylene)))]bis-1,4,8,11-tetraazacyclotetradecane)], wherein said pharmaceutical composition is useful for the treatment of [inflammatory disease; organ transplant rejection; cancer; central nervous system developmental disease; HIV; FIV; vasculature development disease; cardiogenesis developmental disease; haematopoiesis and other] at least one chemokine mediated [diseases or disorders] disorder.